「Amgen prostate cancer」熱門搜尋資訊

Amgen prostate cancer

「Amgen prostate cancer」文章包含有:「TargetingProstate」、「TargetingSTEAP1」、「Amgenstopscancertrial」、「AmgenAxesProstateCancerDrug」、「AMGENTOPRESENTNEWRESEARCHFROM...」、「ProstateCancerDiseaseStateEducationDeck」、「Amgencutsprostatecancerdrugin$650Mwritedown...」、「AMGENPRESENTSNEWTARLATAMABCLINICALDATA...」、「ThreeThingstoLookForwardtoat#ESMO23」、「ThePSMA」

查看更多
Provide From Google
Targeting Prostate
Targeting Prostate

https://www.amgenoncology.com

Therefore, PSMA is an attractive target for the treatment of prostate cancer and potentially other solid tumors.2-4. Learn more about modalities targeting PSMA:

Provide From Google
Targeting STEAP1
Targeting STEAP1

https://www.amgenoncology.com

Discover why STEAP1 (six-transmembrane epithelial antigen of prostate 1) is a therapeutic target and overexpressed in prostate cancer.

Provide From Google
Amgen stops cancer trial
Amgen stops cancer trial

https://www.fiercebiotech.com

Amgen is testing tarlatamab in a form of prostate cancer and has another mCRPC project on the go. ... AmgenTeneobiobispecific antibodiesprostate ...

Provide From Google
Amgen Axes Prostate Cancer Drug
Amgen Axes Prostate Cancer Drug

https://www.biospace.com

The prostate cancer drug was acquired as part of a $900 million upfront buy of Teneobio in 2021. In its reprioritization decision, Amgen said it ...

Provide From Google
AMGEN TO PRESENT NEW RESEARCH FROM ...
AMGEN TO PRESENT NEW RESEARCH FROM ...

https://www.prnewswire.com

These results further justify exploration of this modality as a potential therapy for prostate cancer. Dose expansion and optimization are ...

Provide From Google
Prostate Cancer Disease State Education Deck
Prostate Cancer Disease State Education Deck

https://www.amgenoncology.com

*Amgen is investigating a number of T-cell engaging platforms, including ... mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific ...

Provide From Google
Amgen cuts prostate cancer drug in $650M writedown ...
Amgen cuts prostate cancer drug in $650M writedown ...

https://endpts.com

Amgen discontinues prostate cancer drug in $650M writedown, as obesity pipeline comes into focus in 2024. Andrew Dunn. Biopharma Correspondent.

Provide From Google
AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA ...
AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA ...

https://www.amgen.com

Phase 1 Tarlatamab Study Showed Encouraging Antitumor Activity With Median Duration of Response of 13 Months in Small Cell Lung Cancer.

Provide From Google
Three Things to Look Forward to at #ESMO23
Three Things to Look Forward to at #ESMO23

https://www.amgen.com

New data underscore the potential of Amgen's precision medicine candidates for patients facing high unmet needs in cancer ... prostate cancer ( ...

Provide From Google
The PSMA
The PSMA

https://pubmed.ncbi.nlm.nih.go

Results: AMG 160 induces potent, specific killing of PSMA-expressing prostate cancer cell lines in vitro, with half-maximal lysis of 6-42 pmol/L ...